Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
The Placebo Effect01:54

The Placebo Effect

The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
Regression Toward the Mean01:52

Regression Toward the Mean

Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when researchers try to extrapolate results...
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
Introduction to Language of Pathophysiology ll01:17

Introduction to Language of Pathophysiology ll

This lesson explores key terms that describe how diseases progress, their outcomes, and their distribution in populations.Diagnostic tests identify diseases and monitor treatment. These include blood and urine tests, biopsies, imaging (X-ray, MRI), and detection of infectious agents.Remission is a reduction or disappearance of symptoms.Exacerbation refers to the worsening of symptoms, such as increased wheezing during an asthma attack.A precipitating factor triggers an acute episode, while a...
Blind Procedures02:07

Blind Procedures

Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which child was...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Butterfly gliomas: to biopsy or to ablate - a longitudinal cohort study.

Journal of neuro-oncology·2026
Same author

Non-lytic viral immunotherapy induces long-term glioblastoma survival and tumor-specific immunity without eliciting an antiviral response.

Nature communications·2026
Same author

Prognostic value of postoperative day 1 prolactin following prolactinoma resection.

Journal of neurosurgery·2026
Same author

IL-6 underlies microenvironment immunosuppression and resistance to therapy in glioblastoma.

Cancer research·2026
Same author

Resection versus fenestration for Rathke's cleft cysts: a propensity score-matched analysis of long-term outcomes.

Journal of neurosurgery·2026
Same author

Barriers to expeditious post-operative chemotherapy for patients with glioblastoma.

Clinical neurology and neurosurgery·2026
Same journal

Intramedullary Spinal Cord Tumors.

Neurosurgery clinics of North America·2026
Same journal

Spinal Cord Deformities Associated with Intramedullary Spinal Cord Tumors.

Neurosurgery clinics of North America·2026
Same journal

Radiation Therapy for Spinal Cord Tumors.

Neurosurgery clinics of North America·2026
Same journal

Treatment Strategies of Intramedullary Spinal Cord Tumors.

Neurosurgery clinics of North America·2026
Same journal

Vascular Lesions of the Spinal Cord: Arteriovenous and Cavernous Malformations.

Neurosurgery clinics of North America·2026
Same journal

Hemangioblastomas of the Spinal Cord.

Neurosurgery clinics of North America·2026
See all related articles

Related Experiment Videos

Pseudoprogression and treatment effect.

Arman Jahangiri1, Manish K Aghi

  • 1Department of Neurological Surgery, University of California at San Francisco, 505 Parnassus Avenue, Room M779, San Francisco, CA, USA.

Neurosurgery Clinics of North America
|March 24, 2012
PubMed
Summary
This summary is machine-generated.

Diagnosing glioblastoma recurrence after treatment is challenging. New biomarkers are needed to accurately differentiate treatment effects from tumor progression on MRI scans.

Related Experiment Videos

Area of Science:

  • Neuro-oncology
  • Radiology
  • Biomarker Discovery

Background:

  • Standard glioblastoma treatment involves surgery, radiotherapy, and temozolomide chemotherapy.
  • Post-treatment MRI scans often show enhancing and progressive lesions, complicating diagnosis.
  • Conventional MRI with gadolinium contrast cannot reliably distinguish treatment effects from tumor recurrence.

Purpose of the Study:

  • To highlight the diagnostic challenges in differentiating treatment effects from tumor progression in malignant glioblastoma.
  • To emphasize the need for improved diagnostic tools beyond current imaging modalities.

Main Methods:

  • Review of current diagnostic standards for glioblastoma.
  • Analysis of limitations in conventional MRI interpretation post-treatment.
  • Discussion of emerging imaging and biomarker strategies.

Main Results:

  • Conventional MRI is insufficient for accurate assessment of treatment response versus recurrence.
  • Newer modalities offer some improvement but lack definitive sensitivity and specificity.
  • There is a significant unmet need for reliable biomarkers.

Conclusions:

  • Accurate detection of glioblastoma progression remains a clinical challenge.
  • Novel radiographic or nonradiographic biomarkers are essential.
  • Biomarkers must be validated in large randomized clinical trials for reliable clinical use.